FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594462294> ?p ?o ?g. }

• W2594462294 abstract "Abstract BACKGROUND: Essential thrombocythemia (ET) is thought to derive from the transformation of a multipotent hematopoietic stem cell, but its molecular pathogenesis remains obscure. An acquired mutation in exon 14 of the Janus tyrosine kinase 2 gene (JAK2) leading to a valine --&gt; phenylalanine change at position 617 (JAK2V617F) in the JH2 pseudokinase domain, has been described in Ph negative chronic myeloproliferative disorders (MPD). It can be found in approximately 95% of polycythemia vera (PV) and in approximately 50–60% of essential thrombocythemia (ET) or primary myelofibrosis. The impact of this mutation on clinical phenotype is still debated. We investigated the frequency of JAK2 mutation and its possible impact and correlation with clinical and laboratory features at diagnosis and during follow-up in ET patients (pts), screened for JAK2 mutational status, referred to our division between 1987 and 2008. METHODS and PATIENTS: JAK2V617F mutation analysis was performed on genomic DNA from bone marrow cells or peripheral blood granulocytes in 115 ET (49 males, 66 females) pts, using allele-specific PCR. Clinical and laboratory features were evaluated at diagnosis and during follow-up, in order to compare ET pts harbouring JAK2 mutation versus (vs) pts harbouring wildtype (WT) gene. For statistical analysis, data were processed using the Graph Pad PRISM 5 DEMO Software. Correlations between clinical variables and JAK2 V617F mutational status were tested for significance (p value &lt; 0,05) by using non-parametric methods, in particular the chi-square test or Fisher’s exact test (two by two table) for categorical nominal variables and the Mann-Whitney rank test for ordinal variables. The log-rank (Mantel-Cox) test applied to Kaplan-Meyer method was employed to estimate thrombotic risk and thrombotic event-free-survival (TEFS) RESULTS: 66 ET pts (57,4%) were JAK2V617 positive. JAK2 mutated pts were older (median age 59 vs 48 years, p = 0,0016) and presented at diagnosis significantly higher hemoglobin levels (Hb 14,3 g/dl vs 13,3 g/dl, p= 0,0027), higher hematocrit (Ht 43% vs 39,8%, p &lt; 0,0001) and lower PLT count (PLT 725 vs 841 ×109/L, p = 0,005) respect to WT group. These PV-like features have also maintained during the course of disease, with statistical significance. No difference was observed in term of gender, white blood count, LDH, progression or entity of splenomegaly, and need of cytoreductive therapy between JAK2 mutated and WT ET pts. A highly significant increase of thrombotic complications was registered for JAK2 positive pts. Considering JAK2 WT ET as reference group, the relative risk (RR) of primary thrombotic event was 2,143 (95% CI: 1.053–4.360, p = 0,035) for JAK2 mutated pts (TEFS at 15 years of 60% in JAK2 mutated group vs 75% in WT group, respectively). Arterial events were more frequent than venous events without statistical difference between two ET groups. A trend of higher risk of recurrent thrombosis (p = 0,056) was also showed for JAK2 mutated respect to WT ET pts. There was no difference about the risk of haemorragic complications, time and incidence of evolution in myelofibrosis between JAK2 mutated or WT ET pts. CONCLUSION: In our population, 57,4% ET pts harbor JAK2V617F mutation. This mutation divides ET pts into two distinct subtypes. JAK2 mutated ET pts present older age and laboratory features at diagnosis and during follow-up, compatible with PV-like phenotype. An increased risk of thrombosis, at diagnosis and during the course of disease, has been showed in mutated ET group, in term of recurrent thrombosis too. These observations seem to confirm a phenotype more aggressive since the diagnosis in JAK2 mutated ET group. A possible biological continuum between JAK2 mutated ET and PV, or more in general between JAK2 positive ET and MPD may be supposed." @default.
• W2594462294 created "2017-03-16" @default.
• W2594462294 creator A5005558035 @default.
• W2594462294 creator A5033633636 @default.
• W2594462294 creator A5046490038 @default.
• W2594462294 creator A5047024240 @default.
• W2594462294 creator A5056136982 @default.
• W2594462294 creator A5072928867 @default.
• W2594462294 creator A5074906580 @default.
• W2594462294 creator A5090179703 @default.
• W2594462294 date "2008-11-16" @default.
• W2594462294 modified "2023-10-01" @default.
• W2594462294 title "Impact of JAK2V617F Mutational Status on Clinical and Laboratory Phenotype at Diagnosis and during Follow-up in Patients with Essential Thrombocythemia" @default.
• W2594462294 doi "https://doi.org/10.1182/blood.v112.11.5256.5256" @default.
• W2594462294 hasPublicationYear "2008" @default.
• W2594462294 type Work @default.
• W2594462294 sameAs 2594462294 @default.
• W2594462294 citedByCount "0" @default.
• W2594462294 crossrefType "journal-article" @default.
• W2594462294 hasAuthorship W2594462294A5005558035 @default.
• W2594462294 hasAuthorship W2594462294A5033633636 @default.
• W2594462294 hasAuthorship W2594462294A5046490038 @default.
• W2594462294 hasAuthorship W2594462294A5047024240 @default.
• W2594462294 hasAuthorship W2594462294A5056136982 @default.
• W2594462294 hasAuthorship W2594462294A5072928867 @default.
• W2594462294 hasAuthorship W2594462294A5074906580 @default.
• W2594462294 hasAuthorship W2594462294A5090179703 @default.
• W2594462294 hasConcept C104317684 @default.
• W2594462294 hasConcept C126322002 @default.
• W2594462294 hasConcept C142724271 @default.
• W2594462294 hasConcept C203014093 @default.
• W2594462294 hasConcept C2778837598 @default.
• W2594462294 hasConcept C2779788118 @default.
• W2594462294 hasConcept C2780007613 @default.
• W2594462294 hasConcept C2780076729 @default.
• W2594462294 hasConcept C2781057849 @default.
• W2594462294 hasConcept C501734568 @default.
• W2594462294 hasConcept C54355233 @default.
• W2594462294 hasConcept C71924100 @default.
• W2594462294 hasConcept C86803240 @default.
• W2594462294 hasConcept C89560881 @default.
• W2594462294 hasConcept C90924648 @default.
• W2594462294 hasConceptScore W2594462294C104317684 @default.
• W2594462294 hasConceptScore W2594462294C126322002 @default.
• W2594462294 hasConceptScore W2594462294C142724271 @default.
• W2594462294 hasConceptScore W2594462294C203014093 @default.
• W2594462294 hasConceptScore W2594462294C2778837598 @default.
• W2594462294 hasConceptScore W2594462294C2779788118 @default.
• W2594462294 hasConceptScore W2594462294C2780007613 @default.
• W2594462294 hasConceptScore W2594462294C2780076729 @default.
• W2594462294 hasConceptScore W2594462294C2781057849 @default.
• W2594462294 hasConceptScore W2594462294C501734568 @default.
• W2594462294 hasConceptScore W2594462294C54355233 @default.
• W2594462294 hasConceptScore W2594462294C71924100 @default.
• W2594462294 hasConceptScore W2594462294C86803240 @default.
• W2594462294 hasConceptScore W2594462294C89560881 @default.
• W2594462294 hasConceptScore W2594462294C90924648 @default.
• W2594462294 hasLocation W25944622941 @default.
• W2594462294 hasOpenAccess W2594462294 @default.
• W2594462294 hasPrimaryLocation W25944622941 @default.
• W2594462294 hasRelatedWork W10206933 @default.
• W2594462294 hasRelatedWork W1991764028 @default.
• W2594462294 hasRelatedWork W2195257611 @default.
• W2594462294 hasRelatedWork W2301332035 @default.
• W2594462294 hasRelatedWork W2411786543 @default.
• W2594462294 hasRelatedWork W2433283357 @default.
• W2594462294 hasRelatedWork W2467958615 @default.
• W2594462294 hasRelatedWork W2523306142 @default.
• W2594462294 hasRelatedWork W252666201 @default.
• W2594462294 hasRelatedWork W2537175129 @default.
• W2594462294 hasRelatedWork W2550059784 @default.
• W2594462294 hasRelatedWork W2559547090 @default.
• W2594462294 hasRelatedWork W2582393110 @default.
• W2594462294 hasRelatedWork W2589657471 @default.
• W2594462294 hasRelatedWork W2785018706 @default.
• W2594462294 hasRelatedWork W2790700955 @default.
• W2594462294 hasRelatedWork W2946182169 @default.
• W2594462294 hasRelatedWork W2982450219 @default.
• W2594462294 hasRelatedWork W3032883215 @default.
• W2594462294 hasRelatedWork W3199805964 @default.
• W2594462294 isParatext "false" @default.
• W2594462294 isRetracted "false" @default.
• W2594462294 magId "2594462294" @default.
• W2594462294 workType "article" @default.